tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Chris Schott, 9 are a SELL (4.46%), 54 are a HOLD (26.73%), 139 are a BUY (68.81%).
Analyst Chris Schott, currently employed at JPMORGAN, carries an average stock price target met ratio of 42.87% that have a potential upside of 20.19% achieved within 238 days.
Chris Schott’s has documented 402 price targets and ratings displayed on 30 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on REGN, Regeneron Pharmaceuticals at 09-Jun-2025.
Analyst best performing recommendations are on EQRX (EQRX).
The best stock recommendation documented was for EQRX (EQRX) at 8/16/2022. The price target of $5.5 was fulfilled within 3 days with a profit of $0.67 (13.87%) receiving and performance score of 46.24.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$205
$19.7 (10.63%)
$215
1 months 11 days ago
(14-May-2025)
12/14 (85.71%)
$27.59 (15.55%)
285
Buy
$216
$30.7 (16.57%)
$214
1 months 27 days ago
(29-Apr-2025)
23/26 (88.46%)
$22.49 (11.62%)
431
Buy
$250
$64.7 (34.92%)
$241
1 months 28 days ago
(28-Apr-2025)
12/18 (66.67%)
$57.66 (29.98%)
526
Buy
$240
$54.7 (29.52%)
$210
3 months 20 days ago
(05-Mar-2025)
7/8 (87.5%)
$28.46 (13.45%)
474
Hold
$223
$37.7 (20.35%)
$191
3 months 21 days ago
(04-Mar-2025)
3/4 (75%)
$15.71 (7.58%)
443
Which stock is Chris Schott is most bullish on?
Which stock is Chris Schott is most reserved on?
What Year was the first public recommendation made by Chris Schott?
